ReviewClinical and translational medicine2020
The clinical potential of gene editing as a tool to engineer cell-based therapeutics.
Review in Clinical and translational medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 73 citations in OpenAlex.
- Advanced gene editing technologies for oncology mechanisms, applications, and clinical implementation.Cancer gene therapy · 2026Review
- Gene-Edited Stem Cells for Ischemic Vascular Disease: Current Advances and Future Perspectives.Current issues in molecular biology · 2026Review
- The Mediator Complex: From Transcriptional Regulation to Disease Pathogenesis.International journal of molecular sciences · 2026Review
- The Era of Gene Therapy: The Advancement of Lentiviral Vectors and Their Pseudotyping.Viruses · 2025Review
- Gene editing enables non-invasiveMolecular therapy. Methods & clinical development · 2025Article
- Cell manufacturing for cell-based tissue engineering: a focus on vascularized, skeletal muscle regeneration.Frontiers in chemical engineering · 2025Article
- Genome Editing Approaches Using Zinc Finger Nucleases (ZFNs) for the Treatment of Motor Neuron Diseases.Current pharmaceutical biotechnology · 2025Review
- Emerging Gene-editing nano-therapeutics for Cancer.Heliyon · 2024Review
- Nuclear-Based Labeling of Cellular Immunotherapies: A Simple Protocol for Preclinical Use.Molecular imaging and biology · 2024Article
- Comparative ethical evaluation of epigenome editing and genome editing in medicine: first steps and future directions.Journal of medical ethics · 2024Article
- Exploiting in silico modelling to enhance translation of liver cell therapies from bench to bedside.NPJ Regenerative medicine · 2024Review
- Advances of Genome Editing with CRISPR/Cas9 in Neurodegeneration: The Right Path towards Therapy.Biomedicines · 2023Review
- Observational
- Toward the Development of Epigenome Editing-Based Therapeutics: Potentials and Challenges.International journal of molecular sciences · 2023Review
- Innovative Strategies of Reprogramming Immune System Cells by Targeting CRISPR/Cas9-Based Genome-Editing Tools: A New Era of Cancer Management.International journal of nanomedicine · 2023Review
- Enhanced T cell effector activity by targeting the Mediator kinase module.Science (New York, N.Y.) · 2022Article
- Imaging cellular immunotherapies and immune cell biomarkers: from preclinical studies to patients.Journal for immunotherapy of cancer · 2022Review
- Disruption of HIV-1 co-receptors CCR5 and CXCR4 in primary human T cells and hematopoietic stem and progenitor cells using base editing.Molecular therapy : the journal of the American Society of Gene Therapy · 2022Article
- The role of RNA processing and regulation in metastatic dormancy.Seminars in cancer biology · 2022Review
- Discovery in clinical and translational medicine.Clinical and translational medicine · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
The clinical application of ex vivo gene edited cell therapies first began a decade ago with zinc finger nuclease editing of autologous CD4
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.